The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015.

[1]  Y. Yagi,et al.  Counting mitoses: SI(ze) matters! , 2021, Modern Pathology.

[2]  L. Borsu,et al.  Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes , 2021, Clinical Cancer Research.

[3]  M. Kriegsmann,et al.  Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples , 2021, BMC Cancer.

[4]  Y. Yeh,et al.  Ciliated muconodular papillary tumor/bronchiolar adenoma of the lung. , 2021, Seminars in diagnostic pathology.

[5]  L. Borsu,et al.  Invasive Mucinous Adenocarcinomas with Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  G. Yancopoulos,et al.  Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial , 2021, The Lancet.

[7]  I. Wistuba,et al.  PD-L1 as a biomarker of response to immune-checkpoint inhibitors , 2021, Nature Reviews Clinical Oncology.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[10]  P. Robson,et al.  Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. , 2021, Cancer cell.

[11]  Xue Wu,et al.  Morphological, immunohistochemical, and genetic analyses of bronchiolar adenoma and its putative variants , 2021, The journal of pathology. Clinical research.

[12]  J. Sage.  Faculty Opinions recommendation of SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: A comprehensive immunohistochemical and histopathologic characterization. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[13]  M. Papotti,et al.  Gross Specimen Handling Procedures Do Not Impact the Occurrence of Spread Through Air Spaces (STAS) in Lung Cancer , 2020, The American journal of surgical pathology.

[14]  M. Mino‐Kenudson,et al.  Bronchiolar Adenoma/Pulmonary Ciliated Muconodular Papillary Tumor. , 2020, American journal of clinical pathology.

[15]  Y. Yatabe.  Reassessing the SCLC Subtypes. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  A. Shaw,et al.  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. , 2020, The New England journal of medicine.

[17]  Y. Yatabe,et al.  The Isoform Matters in NUT Carcinoma: A Diagnostic Pitfall of p40 Immunohistochemistry. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  G. Giaccone,et al.  Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. , 2020, The New England journal of medicine.

[19]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[20]  H. Groen,et al.  Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[21]  M. Meyerson,et al.  Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations , 2020, medRxiv.

[22]  E. Sasaki,et al.  AKT1 Mutations in Peripheral Bronchiolar Papilloma , 2020, The American journal of surgical pathology.

[23]  A. Drilon,et al.  Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[24]  E. Feuer,et al.  The Effect of Advances in Lung-Cancer Treatment on Population Mortality. , 2020, The New England journal of medicine.

[25]  L. Spaggiari,et al.  Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. , 2020, Lung cancer.

[26]  C. Dive,et al.  The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  B. Taylor,et al.  The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer , 2020, Clinical Cancer Research.

[28]  Yunchao Huang,et al.  Both the presence of a micropapillary component and the micropapillary predominant subtype predict poor prognosis after lung adenocarcinoma resection: a meta-analysis , 2020, Journal of Cardiothoracic Surgery.

[29]  M. Ladanyi,et al.  Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma , 2020, Modern Pathology.

[30]  A. Nicholson,et al.  A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee , 2020, Journal of Thoracic Oncology.

[31]  G. Pentheroudakis.  Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC). , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  N. Girard,et al.  New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts , 2020, Translational lung cancer research.

[33]  N. Rekhtman,et al.  Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis , 2020, Translational lung cancer research.

[34]  S. Shao,et al.  Pulmonary peripheral glandular papilloma and mixed squamous cell and glandular papilloma frequently harbour the BRAF V600E mutation , 2020, Histopathology.

[35]  Y. Castier,et al.  Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology , 2020, Neuroendocrinology.

[36]  Jacob Josiah Santiago Alvarez,et al.  Genomic landscape of lung adenocarcinoma in East Asians , 2020, Nature Genetics.

[37]  S. Peters,et al.  Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  N. Hanna,et al.  Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Krasnow,et al.  New Approaches to SCLC Therapy: From the Laboratory to the Clinic , 2020 .

[40]  N. Girard,et al.  PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  A. Borczuk,et al.  Genomic Underpinnings of Tumor Behavior in in situ and Early Lung Adenocarcinoma. , 2019, American journal of respiratory and critical care medicine.

[42]  David R. Jones,et al.  SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  Peter Schirmacher,et al.  The 2019 WHO classification of tumours of the digestive system , 2019, Histopathology.

[44]  M. Dietel,et al.  Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options. , 2019, Lung cancer.

[45]  R. Homer,et al.  A Semiquantitative Scoring System May Allow Biopsy Diagnosis of Pulmonary Large Cell Neuroendocrine Carcinoma. , 2019, American journal of clinical pathology.

[46]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[47]  M. Masuda,et al.  Two cases of lung neuroendocrine carcinoma with carcinoid morphology , 2019, Diagnostic Pathology.

[48]  C. Farver,et al.  The Role of Histologic Grading and Ki-67 Index in Predicting Outcomes in Pulmonary Carcinoid Tumors , 2019, The American journal of surgical pathology.

[49]  C. Rudin,et al.  Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[50]  G. Alí,et al.  Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[51]  Aurélie A G Gabriel,et al.  Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids , 2019, Nature Communications.

[52]  W. Weichert,et al.  Classification and Prognostic Stratification of Bronchopulmonary Neuroendocrine Neoplasms , 2019, Neuroendocrinology.

[53]  A. Drilon,et al.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  R. Haba,et al.  Limited Resection Is Associated With a Higher Risk of Locoregional Recurrence than Lobectomy in Stage I Lung Adenocarcinoma With Tumor Spread Through Air Spaces , 2019, The American journal of surgical pathology.

[55]  K. Ashizawa,et al.  Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma , 2019, Nature Communications.

[56]  D. Planchard,et al.  Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[57]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[58]  L. Borsu,et al.  Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[59]  M. Rugge,et al.  Consistency and reproducibility of next‐generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens , 2019, Cancer cytopathology.

[60]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[61]  M. Ladanyi,et al.  Stage IV Lung Carcinoids: Spectrum and Evolution of Proliferation Rate, Focusing on Variants with Elevated Proliferation Indices , 2019, Modern Pathology.

[62]  Yu-An Dong,et al.  Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. , 2019, The oncologist.

[63]  Akihiko Yoshida,et al.  Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[64]  Qifan Yin,et al.  Prognostic Impact of Tumor Spread Through Air Spaces in Non-small Cell Lung Cancers: a Meta-Analysis Including 3564 Patients , 2019, Pathology & Oncology Research.

[65]  M. Mino‐Kenudson,et al.  EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  G. Pelosi,et al.  Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept , 2019, Clinical pathology.

[67]  David R. Jones,et al.  Procedure‐Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤2 cm) Lung Adenocarcinoma: An International Cohort Analysis , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[68]  David R. Jones,et al.  Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)‐Positive T1 Lung Adenocarcinoma: A Propensity Score–Matched Analysis , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[69]  W. Travis,et al.  Implications of the Eighth Edition of the TNM Proposal: Invasive Versus Total Tumor Size for the T Descriptor in Pathologic Stage I‐IIA Lung Adenocarcinoma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[70]  Yingyong Hou,et al.  So-called "non-classic" ciliated muconodular papillary tumors: a comprehensive comparison of the clinicopathological and molecular features with classic ciliated muconodular papillary tumors. , 2018, Human pathology.

[71]  W. Weichert,et al.  Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index > 20% , 2018, Neuroendocrinology.

[72]  Hiroshi I. Suzuki,et al.  An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1–Positive Lung Adenocarcinomas , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[73]  Jason Zhu,et al.  Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG , 2018, The Journal of Nuclear Medicine.

[74]  Y. Akagi,et al.  Tumor Spread Through Air Spaces Identifies a Distinct Subgroup With Poor Prognosis in Surgically Resected Lung Pleomorphic Carcinoma , 2018, Chest.

[75]  E. Baudin,et al.  Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms , 2018, Neuroendocrinology.

[76]  M. Dietel,et al.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal , 2018, Modern Pathology.

[77]  L. Borsu,et al.  Bronchiolar Adenoma: Expansion of the Concept of Ciliated Muconodular Papillary Tumors With Proposal for Revised Terminology Based on Morphologic, Immunophenotypic, and Genomic Analysis of 25 Cases , 2018, The American journal of surgical pathology.

[78]  J. Szustakowski,et al.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.

[79]  J. Berlin,et al.  NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[80]  S. Lantuejoul,et al.  New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[81]  David R. Jones,et al.  Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients. , 2018, Lung cancer.

[82]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[83]  Feifei Yan,et al.  Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy , 2018, Journal of Translational Medicine.

[84]  Martin Vingron,et al.  Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors , 2018, Nature Communications.

[85]  Benjamin Solomon,et al.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[86]  Y. Ishikawa,et al.  Hyalinizing clear cell carcinoma of the bronchial glands: presentation of three cases and pathological comparisons with salivary gland counterparts and bronchial mucoepidermoid carcinomas , 2018, Modern Pathology.

[87]  A. Iafrate,et al.  Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. , 2017, JCO precision oncology.

[88]  Haiquan Chen,et al.  Presence of micropapillary and solid patterns are associated with nodal upstaging and unfavorable prognosis among patient with cT1N0M0 lung adenocarcinoma: a large-scale analysis , 2018, Journal of Cancer Research and Clinical Oncology.

[89]  M. Kris,et al.  The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2) , 2017, Clinical Cancer Research.

[90]  H. Groen,et al.  Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome , 2017, Clinical Cancer Research.

[91]  A. Borczuk,et al.  Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single‐Center Experience , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[92]  L. Prentice,et al.  Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation , 2017, Diagnostic Pathology.

[93]  A. Chapelier,et al.  Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study , 2017, Neuroendocrinology.

[94]  E. Ziv,et al.  Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma , 2017, CardioVascular and Interventional Radiology.

[95]  M. Soda,et al.  Inactivating mutations and hypermethylation of the NKX2‐1/TTF‐1 gene in non‐terminal respiratory unit‐type lung adenocarcinomas , 2017, Cancer science.

[96]  Zhiyong Liang,et al.  Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study. , 2017, Journal of thoracic disease.

[97]  A. Roden,et al.  SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior , 2017, Modern Pathology.

[98]  G. Pelosi,et al.  Distinctive pathological and clinical features of lung carcinoids with high proliferation index , 2017, Virchows Archiv.

[99]  T. Kohno,et al.  Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities , 2017, Modern Pathology.

[100]  K. Higuchi,et al.  A case of anaplastic lymphoma kinase (ALK)‐positive ciliated muconodular papillary tumor (CMPT) of the lung , 2017, Pathology international.

[101]  D. Nonaka,et al.  High-grade Neuroendocrine Carcinoma of the Lung With Carcinoid Morphology: A Study of 12 Cases , 2017, The American journal of surgical pathology.

[102]  W. Travis,et al.  Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer–Specific Death in Squamous Cell Carcinoma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[103]  E. Speel,et al.  Limited additive value of the Ki‐67 proliferative index on patient survival in World Health Organization‐classified pulmonary carcinoids , 2017, Histopathology.

[104]  B. Taylor,et al.  Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. , 2017, Cancer discovery.

[105]  E. Yorke,et al.  Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy. , 2017, International journal of radiation oncology, biology, physics.

[106]  Hancheng Zheng,et al.  Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[107]  A. Nicholson,et al.  The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part‐Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[108]  A. Borczuk,et al.  Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. , 2016, Archives of pathology & laboratory medicine.

[109]  J. Davison,et al.  Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging , 2016, Modern Pathology.

[110]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[111]  L. Macconaill,et al.  KRAS and NKX2‐1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[112]  N. Socci,et al.  Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets , 2016, Clinical Cancer Research.

[113]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[114]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.

[115]  Liping Liu,et al.  Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung , 2016 .

[116]  Yang Zhang,et al.  Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis , 2016, Annals of Surgical Oncology.

[117]  N. Girard,et al.  SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas , 2015, Nature Genetics.

[118]  G. da Cunha Santos,et al.  Preanalytic parameters in epidermal growth factor receptor mutation testing for non–small cell lung carcinoma: A review of cytologic series , 2015, Cancer cytopathology.

[119]  Maristela L Onozato,et al.  Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[120]  S. Broderick,et al.  A Prospective Clinical Trial of Telecytopathology for Rapid Interpretation of Specimens Obtained During Endobronchial Ultrasound-Fine Needle Aspiration. , 2015, The Annals of thoracic surgery.

[121]  E. Siegel,et al.  Rapid on‐site evaluation of EBUS‐TBNA specimens of lymph nodes: Comparative analysis and recommendations for standardization , 2015, Cancer cytopathology.

[122]  A. Warth,et al.  Prognostic Impact of Intra-alveolar Tumor Spread in Pulmonary Adenocarcinoma , 2015, The American journal of surgical pathology.

[123]  H. Asamura,et al.  Ciliated Muconodular Papillary Tumors of the Lung: A Clinicopathologic Analysis of 10 Cases , 2015, The American journal of surgical pathology.

[124]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[125]  David R. Jones,et al.  Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[126]  Boram Lee,et al.  Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma , 2015, Modern Pathology.

[127]  S. Toyooka,et al.  EGFR Mutation Testing Practices within the Asia Pacific Region , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[128]  W. Travis,et al.  Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[129]  Shingo Matsumoto,et al.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. , 2015, Translational lung cancer research.

[130]  B. Reva,et al.  MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking , 2014, Clinical Cancer Research.

[131]  J. Wang,et al.  Ciliated muconodular papillary tumor of the lung: A newly defined peripheral pulmonary tumor with conspicuous mucin pool mimicking colloid adenocarcinoma: A case report and review of literature , 2014, Pathology international.

[132]  M. Tsao,et al.  Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[133]  Yang Zhang,et al.  P-155ALK, ROS1 AND RET FUSIONS IN 1139 LUNG ADENOCARCINOMAS: A COMPREHENSIVE STUDY OF COMMON AND FUSION PATTERN-SPECIFIC CLINICOPATHOLOGIC, HISTOLOGIC AND CYTOLOGIC FEATURES , 2014 .

[134]  Lei Wang,et al.  ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. , 2014, Lung cancer.

[135]  Koji Tsuta,et al.  Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma , 2014, Clinical Cancer Research.

[136]  W. Travis,et al.  Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[137]  E. Brambilla,et al.  On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. , 2014, Lung cancer.

[138]  G. Pelosi,et al.  Grading the neuroendocrine tumors of the lung: an evidence-based proposal. , 2013, Endocrine-related cancer.

[139]  Z Guo,et al.  Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[140]  H. Asamura,et al.  The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. , 2013, Lung cancer.

[141]  A. Nicholson,et al.  Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. , 2013, Archives of pathology & laboratory medicine.

[142]  P. Russell,et al.  Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[143]  M. Ladanyi,et al.  Characteristics of Lung Cancers Harboring NRAS Mutations , 2013, Clinical Cancer Research.

[144]  M. Ladanyi,et al.  KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma , 2013, Modern Pathology.

[145]  Robert L Schmidt,et al.  The influence of rapid onsite evaluation on the adequacy rate of fine-needle aspiration cytology: a systematic review and meta-analysis. , 2013, American journal of clinical pathology.

[146]  M. Meyerson,et al.  Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. , 2013, Molecular cell.

[147]  Y. Yatabe,et al.  HNF4&agr; as a Marker for Invasive Mucinous Adenocarcinoma of the Lung , 2013, The American journal of surgical pathology.

[148]  A. Yoshizawa,et al.  Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[149]  Eric Lim,et al.  Prognostic Significance of Predominant Histologic Pattern and Nuclear Grade in Resected Adenocarcinoma of the Lung: Potential Parameters for a Grading System , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[150]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[151]  W. Bulman,et al.  Acquisition and processing of endobronchial ultrasound-guided transbronchial needle aspiration specimens in the era of targeted lung cancer chemotherapy. , 2012, American journal of respiratory and critical care medicine.

[152]  H. Ji,et al.  RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  Gillian Ellison,et al.  EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples , 2012, Journal of Clinical Pathology.

[154]  Ronglai Shen,et al.  Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers , 2012, Clinical Cancer Research.

[155]  A. Marchevsky,et al.  Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors , 2012, Modern Pathology.

[156]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[157]  A. Nicholson,et al.  Primary Pulmonary Myxoid Sarcoma With EWSR1-CREB1 Fusion: A New Tumor Entity , 2011, The American journal of surgical pathology.

[158]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  Akihiko Yoshizawa,et al.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases , 2011, Modern Pathology.

[160]  W. Travis,et al.  Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[161]  Liu Yan-hui,et al.  Interpretation of Pathological Perspective——International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .

[162]  Manjiri Deshmukh,et al.  Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[163]  K. Kerr,et al.  Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy Specimens , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[164]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[165]  A. Iafrate,et al.  Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.

[166]  Y. Miyagi,et al.  Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung , 2007, Modern Pathology.

[167]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[168]  G. Pelosi,et al.  Typical and Atypical Pulmonary Carcinoid Tumor Overdiagnosed as Small-Cell Carcinoma on Biopsy Specimens: A Major Pitfall in the Management of Lung Cancer Patients , 2005, The American journal of surgical pathology.

[169]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[170]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[171]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[172]  E. Brambilla,et al.  Primary Mucinous (So-called Colloid) Carcinomas of the Lung: A Clinicopathologic and Immunohistochemical Study With Special Reference to CDX-2 Homeobox Gene and MUC2 Expression , 2004, The American journal of surgical pathology.

[173]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[174]  Y. Miyagi,et al.  Aberrant Nuclear Localization and Gene Mutation of β-catenin in Low-Grade Adenocarcinoma of Fetal Lung Type: Up-Regulation of the Wnt Signaling Pathway May Be a Common Denominator for the Development of Tumors that Form Morules , 2002, Modern Pathology.

[175]  K. Kerr,et al.  Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category , 2000, Journal of clinical pathology.

[176]  Y. Shimosato,et al.  Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.

[177]  A. Nicholson,et al.  Solitary pulmonary papillomas in adults: a clinicopathologic and in situ hybridization study of 14 cases combined with 27 cases in the literature. , 1998, The American journal of surgical pathology.

[178]  W. Travis,et al.  Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. , 1998, The American journal of surgical pathology.

[179]  E. Mark,et al.  Pulmonary adenocarcinomas of the fetal lung type: a clinicopathologic study indicating differences in histology, epidemiology, and natural history of low-grade and high-grade forms. , 1998, The American journal of surgical pathology.

[180]  D. Carter,et al.  Tumors of the lower respiratory tract , 1996 .

[181]  R. Hruban,et al.  K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. , 1996, Cancer research.

[182]  A. Foss,et al.  Undefined high-power fields , 1996, The Lancet.

[183]  S. Coghill,et al.  HISTOPATHOLOGISTS, MALIGNANCIES, AND UNDEFINED HIGH-POWER FIELDS , 1989, The Lancet.

[184]  O. Auerbach.  Histological Typing Of Lung Tumors , 1968 .

[185]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[186]  A. Liebow.  Tumors of the lower respiratory tract , 1952 .